Reviews
First-Line EGFR-TKIs With Chemotherapy Improve Survival in EGFR-Mutated NSCLC
Khalid et alAmerican journal of clinical oncology

A systematic review and meta-analysis evaluated the efficacy and safety of adding chemotherapy to first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) compared with EGFR-TKI monotherapy in adults with advanced EGFR-mutated non-small-cell lung cancer (NSCLC). Randomized controlled trials (RCTs) were identified via PubMed, Embase, and the Cochrane Library from inception to August 2026. Data synthesis utilized random-effects models to pool hazard ratios (HRs) and risk ratios (RRs) with 95% confidence intervals, alongside subgroup analyses, sensitivity analyses, trial sequential analysis, and GRADE assessments.
Across seven RCTs encompassing 2,454 patients, combination therapy significantly improved overall survival (HR: 0.64; 95% CI: 0.53–0.77) and progression-free survival (HR: 0.54; 95% CI: 0.45–0.64) relative to EGFR-TKI monotherapy. The objective response rate was also higher in the combination arm (RR: 1.14; 95% CI: 1.07–1.20). Sensitivity analyses supported the robustness of these primary efficacy outcomes, and subgroup analyses demonstrated that the survival and progression benefits remained consistent across different EGFR-TKI generations.
Safety evaluations revealed that adding chemotherapy substantially increased treatment-related toxicity, especially grade ≥3 adverse events and hematologic toxicities. The authors note that while the survival and response advantages support the combination regimen, clinical application requires balancing efficacy gains against the added treatment burden.
Key Takeaways
- First-line EGFR-TKI plus chemotherapy significantly improved overall survival (HR: 0.64; 95% CI: 0.53–0.77), progression-free survival (HR: 0.54; 95% CI: 0.45–0.64), and objective response rate (RR: 1.14; 95% CI: 1.07–1.20) compared with EGFR-TKI monotherapy.
- Combination therapy substantially increased treatment-related toxicity, driven predominantly by higher incidences of grade ≥3 and hematologic adverse events.
- Subgroup analyses demonstrated consistent overall survival and progression-free survival benefits with the combination regimen across EGFR-TKI generations.
Read the original sourceAmerican journal of clinical oncology
